secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001558370-25-001016
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities
--------------------------------------------------------------------------------

- Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.
- Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.
- A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.
- Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.
- Condition: GLYC net cash at closing must be ~$1.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/0001558370-25-001016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/glyc-20250214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer